Jan. 24 Company Quick Takes: Tecentriq misses in bladder cancer; plus Gilead-CDC and PureTech

Phase III miss for Tecentriq as adjuvant for bladder cancer
Genentech Inc. said Tecentriq atezolizumab as post-surgery adjuvant monotherapy vs. no intervention failed to improve disease-free survival, the primary

Read the full 293 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE